VIGAMOX Drug Patent Profile

When do Vigamox patents expire, and when can generic versions of Vigamox launch?

Vigamox is a drug marketed by Harrow Eye and is included in one NDA.

The generic ingredient in VIGAMOX is moxifloxacin hydrochloride. Thirty-six suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vigamox

A generic version of VIGAMOX was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for VIGAMOX

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIGAMOX

Paragraph IV (Patent) Challenges for VIGAMOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIGAMOX	Ophthalmic Solution/Drops	moxifloxacin hydrochloride	0.5%	021598	1	2005-12-22

US Patents and Regulatory Information for VIGAMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003	AT1	RX	Yes	Yes

International Patents for VIGAMOX

See the table below for patents covering VIGAMOX around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	135354
Austria	292127
Australia	1028392
Australia	2528692
Australia	3659489
Australia	6055694

Supplementary Protection Certificates for VIGAMOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0780390	PA2004012	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
0350733	11/2000	Austria		PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
0350733	2001C/030	Belgium		PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621
0780390	PA2004012,C0780390	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309
0350733	300111	Netherlands

VIGAMOX (Moxifloxacin Ophthalmic Solution): Investment Analysis, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

VIGAMOX (generic name: moxifloxacin ophthalmic solution 0.5%) is a broad-spectrum fluoroquinolone antibiotic indicated for bacterial conjunctivitis treatment. As of 2023, VIGAMOX remains a significant asset within ophthalmic antibiotics, with opportunities driven by rising prevalence of eye infections, expanding outpatient ophthalmic procedures, and increasing access to affordable generics.

Key aspects include:

• Industry growth driven by demographic shifts and increasing ophthalmic diseases.
• Patent expiries in the non-U.S. markets opened avenues for generic manufacturers starting around 2013.
• Market competition intensifies with several players holding regulatory approvals for generics.
• The drug’s market value peaked in 2019, with a subsequent decline owing to generic competition.

This analysis assesses the current market landscape, forecasted financial trajectories, and strategic considerations for stakeholders.

---

1. Market Overview and Dynamics

1.1. Market Size and Historical Growth

Year	Global Ophthalmic Antibiotics Market (USD millions)	VIGAMOX Market Share (%)	Key Drivers
2018	1,200	55	Rising bacterial conjunctivitis cases
2019	1,350	50	Increased outpatient procedures
2020	1,400	45	COVID-19 pandemic impact, delayed treatments
2021	1,480	40	Generics entering, pricing pressure
2022	1,560	35	Market saturation, newer alternatives

Source: Market Research Future (2022), QuintilesIMS (2023)

The global ophthalmic antibiotics market is projected CAGR ~4.2% (~2022-2027). VIGAMOX's peak revenues were estimated at ~$180 million (2019), declining post-generic entry.

1.2. Demographic and Epidemiological Drivers

• Aging Population: Increase in ocular surface diseases among seniors.
• Rising Bacterial Conjunctivitis Incidence: Estimated at 3-9% of conjunctivitis cases globally.
• Increasing Outpatient Procedures: Cataract surgeries, LASIK, and other interventions heighten post-operative infection risk, sustaining demand.

1.3. Key Regions and Market Penetration

Region	Market Share (%)	Growth Drivers
North America	40	High outpatient procedure volume, established market access
Europe	25	Aging population, healthcare access
Asia-Pacific	20	Growing healthcare spending, emerging markets
Rest of World	15	Limited penetration, growing unmet needs

---

2. Patent and Regulatory Landscape

2.1. Patent Timelines and Generic Entry

Year	Patent Status	Comments
2003	Patent granted	Patent protection for VIGAMOX in the US (expiry 2018)
2013	Patent expiry (US)	Launch of generic moxifloxacin products begins
2018	US Patent expiry	Entry of multiple generics; increased competition
2020-2023	Regulatory approvals for generics	Several approvals (e.g., Teva, Novartis)

2.2. Regulatory Policies Impacting Market

• FDA & EMA: Rapid approval pathways for generics (ANDA submissions).
• Pricing & Reimbursement: Price reductions driven by payer negotiations, notably post-generic entry.
• Market Exclusivity: No newer formulations with extended exclusivity, constraining innovation-driven premium pricing.

---

3. Competitive Landscape

3.1. Key Players

Company	Product Variants	Market Share (estimated)	Pricing Strategy
Alcon	Original VIGAMOX, generics	35%	Premium pricing pre-2013, now competitive
Teva	Multiple generic formulations	15%	Competitive, aggressive discounting
Novartis (Sandoz)	Generic moxifloxacin	10%	Cost-focused
Others	Various regional generics	40%	Price-sensitive, local manufacturers

3.2. Product Differentiation and Innovation

• Minimal differentiation exists; thus, price competition dominates.
• No recent patent-protected innovations; limited pipeline of next-generation approvals.

3.3. Market Entry Barriers

• Regulatory approval processes.
• Investment in manufacturing compliance.
• Distribution network establishment.

---

4. Financial Trajectory and Investment Outlook

4.1. Revenue Projections

Year	Estimated Revenue (USD millions)	Growth Rate (%)	Market Conditions
2023	100	-5	Generics competition intensifies
2024	95	-5	Price reductions, market saturation
2025	90	-5	Continued generic erosion
2026	85	-6	Potential stabilizing, emerging markets
2027	80	-6	Market stabilization, new entrants

Note: These projections are based on historical decline rates and market saturation.

4.2. Profitability Dynamics

• Gross Margins: Historically around 60-65% pre-generic, decreasing to approximately 30-40% post-generic due to pricing pressures.
• Operational Costs: Manufacturing compliance significantly impacts profitability in generics.
• Pricing Elasticity: Price reductions of 10-20% can significantly diminish revenue streams.

4.3. Investment Considerations

Aspect	Implication
Patent expiry trends	Reduced exclusivity, increased competition
R&D pipeline	Limited; focus on incremental innovation
Geographic expansion	Profitable in emerging markets with lower competition
Regulatory environment	Navigating approval for alternative formulations

---

5. Strategic Implications for Stakeholders

5.1. For Investors:

• Market decline suggests cautious investment in new formulations.
• Opportunities exist in emerging markets with less competition.
• Diversification into combinations or adjunct therapies may be beneficial.

5.2. For Manufacturers:

• Focus on operational efficiencies and cost control.
• Explore product line extensions (e.g., combination eye drops).
• Invest in biosimilar or novel antibiotic research.

5.3. For Policymakers:

• Policies encouraging generic competition can lower patient costs.
• Support for innovation remains critical to address antibiotic resistance.

---

6. Comparative Summary Table

Aspect	VIGAMOX	Competitor Products	Key Takeaways
Market Position	Leading (pre-2013)	Several generics now dominate	Declining due to patent expiry and generics
Revenue Peak	~$180 million (2019)	Lower margins, widespread generics	Market saturation reduced premium pricing
Patent Status	Expired (2018, US)	Multiple approved generics	Intense price competition
Innovation Pipeline	Limited	Few pipeline projects	Focus shifts to incremental improvements

---

7. FAQs

Q1: What is the current market outlook for VIGAMOX?
A: The market is in decline due to patent expiries and increased generic competition, with revenues projected to decrease annually by approximately 5-6% over the next five years.

Q2: How does the regulatory environment impact VIGAMOX’s market?
A: Regulatory approval pathways streamline generic entry, increasing competition and driving down prices, which constrains premium pricing opportunities.

Q3: Are there new formulations or innovations in the pipeline for VIGAMOX?
A: No significant new formulations or patents are currently in advanced development stages; most focus on generics and slight formulation tweaks.

Q4: Which regions present growth opportunities despite market saturation?
A: Emerging markets in Asia-Pacific and Latin America offer growth potential due to lower existing competition and increasing healthcare access.

Q5: What strategic moves should stakeholders consider in light of market dynamics?
A: Diversify product offerings, expand into emerging markets, optimize operational efficiencies, and explore adjacent therapeutic areas.

---

Key Takeaways

• VIGAMOX’s original market dominance has declined due to patent expiry and the advent of multiple generics.
• The current outlook points to steady revenue contraction driven by intense price competition.
• The market landscape favors cost-effective manufacturing and expansion into emerging regions.
• Innovation pipelines are limited; future growth depends on geographic expansion and product line extensions.
• Investors must weigh declining revenues against potential opportunities in less saturated markets and adjacent ophthalmic therapies.

---

References

[1] Market Research Future. (2022). Global Ophthalmic Antibiotics Market Report.
[2] QuintilesIMS. (2023). Pharmaceutical Market Data.
[3] U.S. FDA. (2013-2023). ANDA & NDA Approvals for Ophthalmic Drugs.
[4] Novartis, Alcon, Teva Annual Reports (2018-2023).
[5] World Health Organization. (2022). Global Eye Health and Disease Burden.